Skip to main content
. 2022 Oct 8;15:143. doi: 10.1186/s13045-022-01362-9

Fig. 2.

Fig. 2

FDA-approved therapeutic drugs for lung cancers. a Distribution of therapeutic drugs for lung cancers during the past 31 years (adapted from [126]). b Microtubule inhibitor. c EGFR inhibitors and EGFR-directed mAb. d EGFR- and MET-bispecific antibody and EGFR inhibitor for NSCLC with EGFRex20ins mutations. e ALK inhibitors. f MET inhibitors. g RET inhibitors. h Multitarget TKI. i KRASG12C-targeted small-molecule inhibitor. j DNA topoisomerase inhibitor and DNA alkylating agent for SCLC